Surgical Robotics & AI Report 2026

The surgical robotics market is expanding across procedure categories that have historically operated with very different technology requirements and competitive dynamics. Soft tissue robotic surgery — where the da Vinci platform established market dominance over two decades — is now facing competition from new entrants that have gained FDA clearance and hospital market access. Orthopedic robotic surgery has developed as a distinct market segment with bone-cutting robot systems that provide preoperative planning and intraoperative registration functions qualitatively different from soft tissue telemanipulation. Neurosurgical and interventional robotics are earlier-stage markets with distinct regulatory pathways and clinical adoption patterns.

The regulatory pathway for AI-enabled surgical robotic features requires navigating FDA oversight that has become more attentive to software and AI components of medical devices. The FDA's Software as a Medical Device framework and its guidance on AI/ML-based Software as a Medical Device create a regulatory environment where AI capabilities integrated into surgical platforms require systematic evidence of safety and effectiveness for their specific functions — a standard that is more demanding for autonomous or semi-autonomous surgical functions than for the decision-support and visualization capabilities that characterize current AI surgical tools.

This report is based on a Halkwinds Research survey of 168 surgical service line leaders — chiefs of surgery, surgical robotics program directors, OR nursing directors, and medical device evaluation committee members — at health systems and ambulatory surgical facilities with active or planned robotic surgery programs, conducted between December 2025 and February 2026, supplemented by structured interviews with surgical device organization product and regulatory leaders. Respondents were based in North America (71%), Europe (18%), and Asia-Pacific (8%), with the remainder from other regions. Point estimates carry a margin of error of approximately ±7 percentage points at a 95% confidence level for the full sample, with subsample margins of error (by procedure category and program maturity) ranging from ±10 to ±14 percentage points.

Findings in this report reflect three distinct evidentiary categories, and readers should treat them accordingly: Halkwinds Research primary survey and interview data, presented as such; verified third-party research from organizations including Gartner, Deloitte, McKinsey, and IDC, cited explicitly wherever referenced; and Halkwinds analyst interpretation and synthesis, which represents professional judgment rather than measured fact. No statistic in this report is presented as independently verified unless attributed to a named third-party source. Survey respondents were not Halkwinds clients, and participation was not compensated.

Robotic surgery before 2020 was defined almost entirely by teleoperated soft tissue platforms that extended surgeon dexterity and visualization without providing any independent clinical intelligence — the robot translated the surgeon's hand movements into instrument movements but offered no tissue identification, guidance, or performance feedback of its own. A single manufacturer held a near-monopoly position in soft tissue robotic surgery throughout this period, and platform evaluation was almost exclusively a telemanipulation and ergonomics question rather than an AI capability question.

The 2020-2023 period saw robotic platform competition begin in earnest as new entrants gained FDA clearance in soft tissue and orthopedic robotic surgery, computer vision-based surgical video analytics moved from academic research into commercial performance analytics products, and early AI-assisted tissue visualization features — fluorescence imaging and perfusion assessment among them — reached production deployment on established platforms. Orthopedic robotic surgery matured into a distinct market segment with its own preoperative planning and intraoperative registration technology separate from soft tissue telemanipulation.

The 2024-2026 period, which this report characterizes directly, is defined by the platform competition intensification and AI capability differentiation this report's key findings describe — new entrants challenging the historical soft tissue monopoly with different system economics, AI-assisted guidance and performance analytics becoming genuine platform differentiators rather than experimental add-ons, and early bounded autonomous surgical task automation beginning to move from laboratory demonstration toward initial clinical application.

Surgical robotics platform expansion beyond general and urological surgery into orthopedics, cardiac surgery, and interventional radiology, described in this report's key findings, is a global pattern rather than a market-specific one, though the pace and procedure mix vary by region. Gartner's medical technology research identifies AI-augmented surgical guidance and computer vision-based performance analytics as the fastest-growing capability investment category across robotic platform vendors globally, consistent with this report's own finding that AI capability is becoming a meaningful competitive differentiator alongside core telemanipulation quality.

Regulatory attention to AI components of surgical robotic systems is intensifying in parallel across major device markets, though through different specific mechanisms. In the United States, the FDA's Software as a Medical Device and AI/ML-based Software as a Medical Device guidance frameworks described in this report's industry overview set the evidentiary bar for AI surgical features; the European Union applies its Medical Device Regulation alongside the EU AI Act's provisions for AI systems embedded in medical devices, creating parallel but not identical safety and effectiveness evidence requirements. Deloitte's global medtech outlook research identifies this convergence toward more demanding, AI-specific regulatory evidence standards — rather than regulatory divergence between major device markets — as the dominant multi-year pattern for surgical AI approval pathways.

North America remains the largest and most mature robotic surgery market, driven by the scale of the U.S. hospital and ambulatory surgical facility market, the density of surgical fellowship training programs building robotics into surgeon expectations, and the competitive intensity of health system surgical program investment described in this report's adoption drivers discussion. U.S. health systems in this report's respondent base report the broadest procedure-category robotic adoption and the earliest access to AI-assisted guidance and performance analytics features of any region surveyed.

European health systems operate robotic surgery programs under capital budgeting processes that are frequently more centralized and multi-year than U.S. hospital capital planning, and under the EU Medical Device Regulation's more demanding clinical evidence requirements for novel AI-enabled surgical features. IDC's European healthcare technology research finds this combination produces slower but often more clinically rigorous robotic platform adoption cycles than the U.S. market, with training infrastructure and credentialing pathways developed at a national or regional professional society level rather than solely at the individual health system level.

Asia-Pacific robotic surgery investment is growing quickly from a lower installed-base per capita than North America or Europe, concentrated in markets including Japan, South Korea, Australia, and China, where both domestic platform manufacturers and established international vendors are competing for hospital market access. Gartner's regional medtech research identifies orthopedic and general surgery robotics as the fastest-growing procedure categories in the region, with AI-assisted guidance and surgical performance analytics adoption still earlier-stage relative to North America and Europe.

Soft tissue robotic surgery — urology, general surgery, and gynecology — remains the largest procedure category by installed base and case volume, and is the category where the historical single-platform market dominance described in this report's historical timeline is now facing the most direct new-entrant competition. Evaluation criteria in this category increasingly weigh AI-assisted guidance and performance analytics capability alongside core telemanipulation quality, since surgeon proficiency and instrument ecosystem maturity across competing platforms are converging faster than in newer procedure categories.

Orthopedic robotic surgery operates on a fundamentally different technology model than soft tissue telemanipulation — bone-cutting robotic systems built around preoperative CT- or image-based surgical planning and intraoperative registration rather than real-time surgeon-driven instrument control. This report's key findings note that orthopedic robotics has developed as a distinct market segment with its own evaluation criteria, vendor landscape, and training requirements, and health systems building multi-category robotic portfolios should not apply soft tissue platform evaluation frameworks to orthopedic platform decisions.

Cardiac surgery and interventional radiology robotics are earlier-stage sub-verticals where clinical evidence, regulatory clearance scope, and vendor maturity are less developed than in soft tissue or orthopedic robotics. Organizations evaluating platforms in these categories should weight procedure-specific clinical evidence and regulatory clearance scope more heavily than platform brand reputation carried over from soft tissue or orthopedic robotic surgery experience, since capability and evidence maturity do not transfer uniformly across procedure categories from the same vendor.

AI-assisted surgical guidance platforms use computer vision and machine learning to analyze the surgical field in real time, providing the operating surgeon with tissue identification overlays, anatomical boundary visualization, and instrument proximity alerts that augment the surgeon's visual field beyond what the human visual system can detect. These capabilities have particular clinical significance in procedures with narrow anatomical margins — rectal cancer resection, hepatobiliary surgery, head and neck surgery — where inadvertent injury to critical structures creates serious clinical consequences. The intraoperative guidance capability is distinct from the telemanipulation capability of the robotic platform itself and is being developed by both robotic platform vendors and independent intraoperative intelligence software companies.

Surgical performance analytics platforms apply computer vision analysis to surgical video to quantify surgical technique parameters — instrument motion economy, tissue handling, procedural step completion rates — that have historically been assessable only through qualitative observer scoring. Automated performance measurement creates opportunities for objective surgical skills assessment, training program optimization, and quality improvement feedback that are not feasible with traditional surgeon performance evaluation approaches. The clinical and administrative implications of these platforms are significant: organizations with objective surgical performance data are developing quality programs that were previously limited by the absence of scalable measurement tools.

Surgical robotics capital economics have historically been dominated by three cost components that health systems should budget as distinct lines rather than a single program cost: system acquisition cost, annual maintenance and service contract cost, and per-case disposable instrument cost, with this report's key findings noting that per-case instrument and maintenance cost is frequently the more impactful driver of total program economics over a platform's operating lifecycle than the initial acquisition price. Training infrastructure — simulation training resources, surgeon mentoring programs, and OR team training — is a budget line this report's key findings identify as substantially underestimated by organizations that concentrate capital planning on system acquisition alone.

New entrant competition in soft tissue robotic surgery is changing the economics available to health systems, with alternative platform vendors offering different capital and per-case pricing structures, including in some cases leasing arrangements, than the historical single-vendor cost model. IDC's medical technology market research finds that the presence of credible alternative platforms has measurably changed the negotiating dynamic for system renewal and expansion contracts with established vendors, giving health systems in active negotiation cycles leverage they did not have when soft tissue robotic surgery was effectively a single-vendor market. AI-enabled guidance and performance analytics features are typically priced as an incremental capability layer on top of core platform costs and should be evaluated against their specific clinical and quality-improvement return rather than bundled into general platform cost comparison.

Surgical program competition and patient volume attraction are the primary market adoption drivers for robotic surgery investment at most health systems. Patients seeking robotic surgery — driven by awareness of minimally invasive benefits in recovery time and complication rates for qualifying procedures — preferentially choose facilities with robotic surgery capabilities. Health systems in competitive markets have consistently found robotic surgery program investment to be a patient volume driver that generates downstream procedural revenue from patient relationships that are retained beyond the robotic procedure itself.

Surgeon recruitment and retention is a secondary adoption driver that is increasingly significant as robotics proficiency becomes part of surgeon identity and training expectations. Surgeons completing fellowship training in surgical specialties where robotics is prevalent expect robotic platform access at their practice institutions. Health systems without current-generation robotic platforms face competitive disadvantage in surgeon recruitment relative to peer institutions with comprehensive robotic surgery programs — a constraint that affects the sustainability of surgical service lines beyond the direct financial return from robotic procedures.

The business case for surgical robotics investment operates through multiple financial pathways that require procedure-specific modeling. Volume growth from patient preference for minimally invasive robotic approaches is the largest financial driver at most institutions, as increased procedure volume generates contribution margin that offsets system acquisition, maintenance, and disposable instrument costs. Reduced length of stay for robotic versus open procedures in qualifying patient populations generates additional financial benefit through bed capacity optimization and reduced post-operative resource utilization — benefits that are more significant for inpatient-heavy surgical service lines operating under capacity constraints.

AI-enabled surgical analytics and quality improvement programs are demonstrating ROI through complication reduction rather than volume growth. Programs using surgical video analytics to identify technique optimization opportunities and provide structured feedback to surgeons are reporting reductions in specific complication rates — surgical site infection, anastomotic leak, conversion to open — that generate both clinical benefit and financial return through reduced post-operative complication management costs. The complication reduction ROI pathway is more analytically complex than volume growth modeling but may be more durable in value-based care environments that reward clinical outcomes rather than procedural volume.

The clearest quantifiable benefits of AI-augmented surgical robotics map directly to this report's own business impact findings: volume growth from patient preference for minimally invasive robotic approaches that generates contribution margin exceeding system acquisition, maintenance, and disposable instrument cost, and reduced length of stay for robotic versus open procedures in qualifying patient populations that improves bed capacity utilization for inpatient-heavy surgical service lines. AI-enabled surgical video analytics adds a further quantifiable benefit category — programs using structured technique feedback are reporting measurable reductions in specific complication rates including surgical site infection, anastomotic leak, and conversion to open, each of which carries its own avoided-cost value through reduced post-operative complication management.

Training and credentialing program quality is a second, less financial but equally quantifiable benefit dimension: this report's implementation considerations findings show that surgeons completing structured simulation curricula before independent practice demonstrate faster proficiency curves and lower complication rates during the learning period than those trained through unstructured mentored cases alone — a benefit that compounds across every surgeon a program trains over its lifetime. McKinsey's medical technology research finds that health systems explicitly linking surgical performance analytics output to individual surgeon coaching and credentialing renewal decisions achieve measurably faster program-wide proficiency gains than systems deploying the same analytics technology without that operational linkage, underscoring that the technology alone does not generate the benefit — the training and quality program built around it does.

Surgeon training program design is the implementation factor most consistently correlated with successful robotic surgery program outcomes. Surgeons who complete structured robotic skills curricula before performing procedures on patients demonstrate faster proficiency curves, lower complication rates in the learning period, and higher sustained case volumes than those trained through unstructured mentored cases. Programs should invest in simulation training resources — robotic surgical simulators that provide structured skills modules and objective performance measurement — and establish minimum simulation training requirements before permitting independent robotic procedures.

Operating room team training and workflow redesign are implementation requirements that are underweighted relative to surgeon training in most robotic program planning. The operating room nursing and scrub technician teams supporting robotic cases require training on robotic system setup, instrument handling, and case flow that differs materially from open and laparoscopic cases. OR teams that are not fully proficient with robotic system operation create case time inefficiency and equipment handling errors that affect both patient safety and the financial economics of robotic program operations.

• Design surgeon training programs with simulation prerequisites before independent procedure performance — structured simulation training is correlated with better early-case outcomes.
• Budget for OR team and nursing training as a material program component — inadequate team training creates case time inefficiency and equipment safety risk.
• Evaluate AI guidance capabilities as distinct platform dimensions from telemanipulation capability — AI features require procedure-specific evidence assessment.
• Assess disposable instrument and maintenance cost per case as primary ongoing program economics — system acquisition cost is often less impactful than per-case variable cost over a platform lifecycle.
• Negotiate system maintenance and upgrade terms before finalizing platform selection — surgical robotics vendor contracts vary significantly in maintenance, upgrade access, and instrument pricing flexibility.
• Establish credentialing pathways before program launch — credentialing requirements for robotic procedures should be developed with medical staff leadership before surgeon training begins.

Learning curve complications represent the most significant patient safety risk dimension of surgical robotics program development. All surgical procedures have a learning curve during which complication rates are higher than at surgeon proficiency — and robotic procedures, which require adaptation of surgical technique to a new modality, have learning curves that must be managed with structured training, case selection, and mentoring programs. Organizations that rush to build case volume without adequate surgeon preparation — driven by program revenue pressure or competitive urgency — create patient safety risk during the learning period that is both ethically and legally consequential.

Platform technology lock-in is a strategic risk that is particularly significant in surgical robotics because instrument compatibility and surgeon proficiency are platform-specific. Surgeons trained on one robotic platform cannot transfer that proficiency immediately to a different platform — retraining takes time and carries a renewed learning curve risk. Health systems that commit deeply to a single robotic platform through large capital investment, surgeon training, and long-term maintenance contracts face significant switching costs if competitive or technology factors make platform transition strategically desirable.

• Manage learning curve risk through structured case selection criteria and mentoring requirements — volume pressure should not override patient safety criteria for early robotic cases.
• Assess platform technology lock-in risk before large capital commitments — surgeon retraining costs and learning curve renewal are material switching cost components.
• Evaluate AI surgical guidance claims against procedure-specific clinical evidence — general robotic surgery outcome data should not be applied to AI-specific feature evaluation.
• Establish robotic equipment malfunction protocols — hardware and software failures during procedures require clear response protocols developed before program launch.
• Monitor malpractice and legal risk environment for robotic surgery — liability frameworks for AI-assisted surgical complications are still being established by case law.

Surgical robotic platforms are increasingly networked — remote diagnostics access for vendor service teams, software update delivery, and integration with hospital EHR, PACS, and imaging systems create an attack surface that health system IT and biomedical engineering security programs must actively manage. HIMSS's medical device security research identifies robotic surgical systems and other networked capital equipment as a growing focus area for health system medical device security programs, given the direct patient-safety implications of any connectivity disruption or unauthorized access, distinct from the general malfunction and legal risk this report's Risks & Challenges section addresses. Surgical video retained for AI performance analytics, described in this report's Quantified Benefits findings, also carries HIPAA-regulated PHI considerations distinct from operational device telemetry, requiring governance frameworks that specify retention period, de-identification approach, and third-party analytics vendor data access before any video-based analytics program is deployed at scale.

The platform competition this report's Cost Analysis describes also introduces vendor viability risk that did not meaningfully apply when soft tissue robotic surgery was effectively a single-vendor market. Because surgical robotic capital equipment carries a multi-year service and instrument dependency lifecycle, evaluation committees should treat vendor financial stability, service infrastructure maturity, and installed base scale as explicit risk factors at the time of purchase and for the duration of the platform's operating life — not only for newer entrants seeking hospital market access, but for any vendor whose long-term maintenance and instrument supply commitments underpin a multi-year clinical program.

• Treat networked surgical robotic systems as part of the medical device cybersecurity program, not solely biomedical engineering equipment maintenance — vendor remote access and software update pathways require security review.
• Establish a specific data governance policy for surgical video used in AI performance analytics, covering retention, de-identification, and third-party vendor access, separate from general device operational data policy.
• Assess vendor financial stability and service infrastructure maturity as a formal criterion in platform evaluation, particularly for newer entrants without an established multi-region service network.
• Review compliance obligations under the FDA's premarket and postmarket cybersecurity guidance for networked medical devices alongside HIPAA Security Rule requirements when scoping surgical robotics IT integration.

Health systems evaluating surgical robotics investments should build procedure-specific business cases rather than applying a single robotic program ROI model across all surgical services. The financial returns, training requirements, competitive dynamics, and clinical evidence profiles differ significantly across procedure categories — the soft tissue robotic surgery case in urology and gynecology operates in a very different competitive environment from orthopedic robotics or emerging cardiac applications. Organizations that apply differentiated analysis by procedure category make better platform and investment sequencing decisions than those using a single robotic program framework across all services.

AI surgical capability evaluation should be treated as a distinct dimension from platform telemanipulation evaluation. The vendors leading in AI-assisted guidance, performance analytics, and training optimization are not uniformly the same as those leading in telemanipulation system design. Organizations evaluating AI surgical technology should assess the clinical evidence, regulatory status, and integration architecture of specific AI features rather than assuming that AI capability is uniformly distributed across platform vendors.

Community health systems and ambulatory surgical centers with constrained capital budgets should prioritize procedure-specific business case discipline over program breadth — this report's strategic recommendations emphasize building the business case category by category rather than applying a single robotic program ROI model, and smaller organizations benefit most from concentrating initial investment in the procedure category with the strongest local patient volume and surgeon recruitment case rather than building multi-category robotic portfolios prematurely. Given the training infrastructure investment this report's key findings identify as commonly underestimated, community systems should budget simulation training, OR team training, and credentialing pathway development as fixed program costs from the outset rather than assuming they can be added later at lower incremental cost.

The new entrant competition in soft tissue robotic surgery described in this report's cost analysis gives smaller health systems a negotiating opportunity that did not exist when the category was effectively a single-vendor market — organizations planning initial platform acquisition or renewal should solicit competitive proposals from multiple vendors even if the incumbent platform is the likely final choice, using alternative vendor terms as leverage in maintenance and instrument pricing negotiations.

Surgical AI and medical device startups should treat FDA regulatory strategy as a foundational product decision rather than a late-stage compliance step, since this report's industry overview finds that the evidentiary bar for AI surgical features rises sharply with functional autonomy — decision-support and visualization features face a materially lower evidence bar than semi-autonomous or autonomous surgical functions. Startups building intraoperative guidance or performance analytics products should design clinical evidence generation plans around the specific procedure categories and clinical claims they intend to make, rather than pursuing broad platform-agnostic development and retrofitting regulatory evidence afterward.

Startups pursuing surgical data network strategies — described in this report's future outlook as a durable source of competitive advantage — should build institutional data-sharing partnerships and governance frameworks as core go-to-market infrastructure from inception, since health systems' willingness to share surgical video and outcome data depends heavily on clear, contractually specified data use, access, and protection terms. Startups competing against the established soft tissue robotic surgery incumbent should also expect health system evaluation committees to weigh installed surgeon training network size and vendor service maturity alongside clinical evidence, and should plan commercial and clinical evidence strategy accordingly rather than competing on technology claims alone.

Autonomous surgical task automation will advance from laboratory demonstration to initial clinical deployment in specific bounded applications over the next three to five years. Early autonomous applications are most likely in structured, repetitive surgical subtasks with high anatomical predictability — tissue dissection along defined anatomical planes, suturing of standardized configurations, or anastomosis construction — rather than the full complexity of open-ended surgical decision-making. The regulatory pathway for autonomous surgical function will require robust evidence standards that are still being defined, making regulatory engagement a critical part of commercial development planning for surgical AI companies.

Surgical data networks — aggregated surgical video and outcome datasets that enable AI model training across multi-institutional patient populations — will define the competitive advantage of surgical AI platforms over the next decade. Organizations and vendors that build data network effects through institutional partnerships, outcome data sharing programs, and AI-driven performance improvement programs will have training data advantages that create durable competitive moats in surgical AI development. Health systems participating in surgical data networks should ensure clear data governance frameworks that specify how their surgical data is used, accessed, and protected.

This report draws on Halkwinds' direct advisory and implementation engagements and the primary survey described in the Methodology section as its core evidence base, supplemented by publicly available third-party research used strictly for external validation and context. The following sources informed the analytical framing of this report and are cited here as verified external references, distinct from Halkwinds' own survey and engagement-derived findings: Gartner medical technology and surgical robotics market research; Deloitte's global medtech and healthcare technology outlook research; McKinsey's medical technology and health system performance research; IDC's medical technology and regional healthcare technology market research; HIMSS's medical device cybersecurity research; the U.S. Food and Drug Administration's Software as a Medical Device and AI/ML-based Software as a Medical Device guidance frameworks; and the European Union's Medical Device Regulation and AI Act provisions applicable to AI systems embedded in medical devices. Where this report references findings from these sources, it does so as attributed third-party analysis or official guidance rather than Halkwinds' own primary research, and readers should consult the original publications for full methodology and data currency before citing specific figures independently.

Halkwinds is a technology strategy and engineering firm specializing in healthcare AI and digital health product development. Halkwinds' surgical technology practice covers robotic surgery program strategy, surgical AI platform evaluation, OR technology integration, and medical device software development for health systems and surgical device organizations.

Halkwinds Research publishes practitioner analysis on emerging healthcare technology trends. Readers seeking to engage Halkwinds on surgical robotics strategy, AI surgical platform evaluation, or medical device software development can explore the firm's capabilities at halkwinds.com or review the CareAxis healthcare platform.